Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
暂无分享,去创建一个
[1] S. Hammer,et al. The values of quantitative serum HIV-1 RNA levels and CD4 cell counts for predicting survival time among HIV-positive individuals with CD4 counts of ⩽ 50 × 106 cells/l , 2000, AIDS (London).
[2] J. Goedert,et al. Plasma HIV Viral Load in Patients with Hemophilia and Late-Stage HIV Disease: A Measure of Current Immune Suppression , 1999, Annals of Internal Medicine.
[3] F Miedema,et al. Normal telomere lengths in naive and memory CD4+ T cells in HIV type 1 infection: a mathematical interpretation. , 1999, AIDS research and human retroviruses.
[4] G. Pantaleo,et al. T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy (review). , 1999, International Journal of Molecular Medicine.
[5] M A Fischl,et al. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[6] H. Ullum,et al. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection , 1998, AIDS.
[7] T. Perneger,et al. A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4 + Cell Counts in HIV-Infected Patients , 1998 .
[8] I Spijkerman,et al. AIDS prognosis based on HIV‐1 RNA, CD4+ T‐cell count and function: markers with reciprocal predictive value over time after seroconversion , 1997, AIDS.
[9] M. Prins,et al. Early and late HIV‐1 RNA level and its association with other markers and disease progression in long‐term AIDS‐free homosexual men , 1997, AIDS.
[10] M. Hughes,et al. Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response , 1997, Annals of Internal Medicine.
[11] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[12] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .
[13] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[14] J. Bartlett,et al. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. , 1996, AIDS.
[15] T. Perneger,et al. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. , 1996, The Journal of infectious diseases.
[16] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[17] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[18] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[19] C. Loveday,et al. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count , 1995, The Lancet.
[20] A. Perelson,et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.
[21] Martin A. Nowak,et al. Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.
[22] R. Gelman,et al. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.
[23] A. Fauci,et al. The immunopathogenesis of human immunodeficiency virus infection. , 1993, The New England journal of medicine.
[24] J. Kagan,et al. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. , 1993, Clinical immunology and immunopathology.
[25] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[26] D. Katzenstein,et al. Inhibition of human immunodeficiency virus gene amplification by heparin , 1991, Journal of clinical microbiology.
[27] M. Salimans,et al. Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.
[28] R. Simon,et al. Flexible regression models with cubic splines. , 1989, Statistics in medicine.
[29] Steven G. Deeks,et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans , 1999, Nature Medicine.
[30] H. Schuitemaker,et al. Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. , 1998, Immunology today.
[31] S. Hammer,et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, The Journal of infectious diseases.
[32] Ann Collier,et al. Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease , 1995, Annals of Internal Medicine.